First of its Kind Study Written by Dr. Andrew
Davis and Published in Peer-Reviewed “Journal of Drug Issues”4000
Medical Cannabis Patient Study Leveraged Aleafia Health’s
Proprietary Medical Cannabis Database
Aleafia Health Inc. (TSXV: ALEF, OTC: ALEAF, FRA: ARAH)
(“
Aleafia Health” or the
“
Company”), announced the results of a 4,000
medical cannabis patient study (“
The Study”)
examining changes in employment and disability status among medical
cannabis patients. The study was published on March 13, 2019 in the
peer-reviewed Journal of Drug Issues, and is, to the Company and
author’s knowledge, the first to ever directly observe
physician-led medical cannabis usage and labour force status over
time.
SIGN-UP HERE to get the latest Aleafia Health press
releases delivered to your inbox.
The Study found a mild net improvement in employment after
starting medical cannabis treatment, along with a reduction in
unemployment and self-identified disability preventing employment.
This is particularly notable as the vast majority of patients
reported suffering from chronic illnesses, including pain, anxiety
and depression, conditions which research indicates would
ordinarily lead to a decrease in employment and labour force
participation. Epileptic patients were the most likely to see
improvements in their labour status.
“These findings serve both to motivate further medical research
into the interactions of cannabis with a variety of medical
conditions and pharmaceutical therapies, while also contributing to
the public health debate over cannabis,” said study author Dr.
Andrew Davis. “The improvement in the employment prospects of
epileptic patients is particularly encouraging and merits further
investigation by medical professionals. I would caution that only
patients undergoing physician-led medical cannabis treatment were
monitored, not individuals using cannabis recreationally or
self-medicating.”
Dr. Davis leveraged Aleafia Health’s 10 million point medical
cannabis patient dataset. The Company believes it maintains the
world’s largest medical cannabis patient dataset and is deploying
the data for unique insights in medical cannabis treatment and
product development best practices. Dr. Davis has had an
intermittent and unrelated consulting relationship with the
Company.
Aleafia Health’s support for ongoing research efforts are aimed
at developing evidence-based, proprietary treatment methods and
products for chronic illnesses including pain, insomnia, anxiety
and eating disorders. The Company recently supported a published
study on medical cannabis patients using prescription
benzodiazepines. It is currently undertaking an insomnia study in
partnership with Cronos Group Inc.
“Aleafia Health continues to treat a high volume of patients
suffering from epilepsy and the results of this study further
cement the conclusion that many of our physicians have already made
regarding the effectiveness of medical professional cannabis care,”
said Aleafia Health Chief Medical Officer Dr. Michael Verbora. “We
will continue to leverage our IP and leading cannabis data to
further advance patient care through advanced treatment methods and
specialized product development.”
LEARN MORE: http://www.aleafiahealth.com
For Investor & Media Relations, please
contact:
Nicholas Bergamini, VP, Public
Affairs416-860-5665IR@AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a leading, vertically integrated cannabis
health and wellness company with four primary business units:
Cannabis Cultivation & Products, Health & Wellness Clinics,
Cannabis Education, and Consumer Experience with ecommerce, retail
distribution and provincial supply.
Aleafia Health owns three major cannabis product &
cultivation facilities where it produces a diverse portfolio of
commercially proven, high-margin derivative products including
oils, capsules and sprays. Aleafia Health operates the largest
national network of medical cannabis clinics and education centres
staffed by MDs, nurse practitioners and educators.
Aleafia Health maintains a medical cannabis dataset with over 10
million data points to inform proprietary illness specific product
development and treatment best practices. The Company is committed
to creating sustainable shareholder value and has been named the
2019 top performing company of the year by the TSX Venture
Exchange.
Learn more at www.AleafiaHealth.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements and
information that are based on the beliefs of management and reflect
the Company's current expectations. When used in this press
release, the words "estimate", "project", "belief", "anticipate",
"intend", "expect", "plan", "predict", "may" or "should" and the
negative of these words or such variations thereon or comparable
terminology are intended to identify forward-looking statements and
information.
The forward-looking statements and information in this press
release includes information relating to the implementation of
Aleafia Health's business plan. Such statements and information
reflect the current view of the Company with respect to risks and
uncertainties that may cause actual results to differ materially
from those contemplated in those forward-looking statements and
information.
By their nature, forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause our
actual results, performance or achievements, or other future
events, to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Such factors include, among others, the
following risks: risks associated with the implementation of
Aleafia Health's business plan and matters relating thereto, risks
associated with the cannabis industry, competition, regulatory
change, the need for additional financing, reliance on key
personnel, the potential for conflicts of interest among certain
officers or directors, outcomes of future medical studies and the
volatility of the Company's common share price and volume.
Forward-looking statements are made based on management's beliefs,
estimates and opinions on the date that statements are made, and
the Company undertakes no obligation to update forward-looking
statements if these beliefs, estimates and opinions or other
circumstances should change. Investors are cautioned against
attributing undue certainty to forward-looking statements.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/ad4d2599-1821-4b8a-9b70-70c78eb8e121
Aleafia Health (TSXV:ALEF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aleafia Health (TSXV:ALEF)
Historical Stock Chart
From Apr 2023 to Apr 2024